Purchase Order 124M5518P0103
- Not listed
- The U.S. government awarded a $7,500 firm fixed-price purchase order to 10X Genomics, Inc. for a 12-month Chromium Assurance Plan covering instrument serial number 10492, with performance from September 29, 2019 through September 28, 2020. The contract, issued on March 28, 2019, supports a civilian federal agency within the Southeast Area and will be performed at 10X Genomics' headquarters in Pleasanton, California. No set-aside designation was applied to this award. 10X Genomics is a...
- 10X Genomics, Inc. has been awarded a firm fixed price purchase order valued at $20,500 by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. The contract is for the Chromium IX/X Assurance Plan to be performed in Pleasanton, California through February 2025 with no set-aside designation used. As a manufacturer of single-cell and spatial analysis products and services, 10X Genomics will deliver its Chromium...
- The Food and Drug Administration (FDA) awarded a $90,562 firm fixed-price purchase order to 10X Genomics, Inc. for a Chromium X instrument and accessory kit, with performance completion targeted for September 7, 2023. The award, issued on September 7, 2022, was made without a set-aside designation and specifies Laurel, Maryland as the place of performance. 10X Genomics is a leading biotechnology company headquartered in Pleasanton, California, specializing in advanced genomic analysis...
- This federal contract award to 10X Genomics, Inc. is for the supply of a CHROMIUM CONTROLLER valued at $144,840.00. The award was made by the Southeast Area division of a civilian federal agency, likely the National Institutes of Health (NIH), on September 2, 2016. The contract has a firm fixed price and an ultimate completion date of October 28, 2016. 10X Genomics is a life sciences technology company that specializes in advanced genomic analysis platforms and provides cutting-edge solutions...
- The U.S. government awarded a firm fixed-price purchase order valued at $9,808.00 to 10X Genomics, Inc. for one Chromium Genome Chip Kit V2 (48 reactions) on September 19, 2017. The contract, which was performed in Pleasanton, California, carried an ultimate completion date of October 18, 2017. No set-aside designation was applied to this procurement, and the funding was provided by a civilian federal agency within the Southeast Area. 10X Genomics, Inc., a biotechnology company specializing in...
- This is a firm fixed-price purchase order awarded by the National Institute of Child Health and Human Development, a civilian federal agency, to 10X Genomics, Inc., a biotechnology company in Pleasanton, California. The $9,999.00 order is for the Chromium Next GEM product, which is used for advanced single-cell and spatial genomic analysis. 10X Genomics has been awarded multiple federal contracts and task orders from NIH institutes, often with small business set-aside designations, to provide...
- This is a firm fixed-price purchase order contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to 10X Genomics, Inc. The contract has a potential value of $14,000.00 and is for the delivery of 10X Genomics' Chromium Assurance Plans, which include their genomic analysis platforms, reagents, instruments, and bioinformatics software. 10X Genomics is a life sciences technology company that...
- This is a firm fixed price purchase order awarded by the Northeast Area of a civilian federal agency to 10X Genomics, Inc. for $21,888.50. The award is for 10X Genomics Chromium consumables to support single cell sequencing. The contract has no set-aside designation and is intended to supply these genomics products and services to support the agency's biomedical research efforts, particularly by the National Institutes of Health and its various institutes and centers. 10X Genomics is a life...
- This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to 10X Genomics, Inc. for a Chromium Single Cell Analyzer. The $84,432.00 contract has an ultimate completion date of April 7, 2018. 10X Genomics is a life sciences technology company that provides genomic analysis platforms, reagents, instruments, and bioinformatics software for single-cell and spatial analysis...
- This firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to 10X Genomics, Inc., a life sciences technology company, for the provision of one (1) unit of a Chromium Single Cell Controller with accessories. The contract has a ceiling value of $90,382.25 and a period of performance through June 30, 2025. No set-aside designation was used for this award. 10X Genomics has previously provided specialized genomics products and services, such as kits for single-cell RNA...
10X Genomics, Inc. was awarded a purchase order on September 22, 2018, valued at $12,500 for a 12-month Chromium Assurance Plan covering maintenance and support services for a Chromium Controller instrument (Serial Number 10492). The contract was awarded without set-aside designation under a firm fixed-price arrangement by a civilian federal agency within the Southeast Area. Performance of this service is based in Pleasanton, California, with an ultimate completion date of September 28, 2019. This award reflects the federal government's reliance on 10X Genomics' advanced genomic analysis platforms to support biomedical research initiatives across multiple agencies. 10X Genomics specializes in single-cell and spatial transcriptomics technologies and has established itself as a key supplier to the National Institutes of Health and related research institutions. The Chromium Controller is a critical instrument in the company's portfolio for genomic research applications, and the assurance plan ensures continued operational capability for the funded research mission. The company maintains a substantial indefinite delivery contract valued at up to $7 million with the National Institute on Aging through July 2029, underscoring the federal government's significant investment in its genomic analysis capabilities for disease research and biomedical advancement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.5k | 9/22/18 |